PURPOSE: To evaluate the results and quality of life of patients with resistant of castration-resistant tumors previously treated with Insulin-potentiation therapy (IPT) combined with hormone therapy.
MATERIALS AND METHODS: Sixteen patients with metastasis prostate tumors after bilateral castration, androgenic blockade, and progression of the disease were observed during the study. The patients were divided into two groups: group A consisting of 8 patients treated with low-dose chemotherapy Epirubicin, Vinblastine, and Cyclophosphamide combined with LHRH agonist and group B consisting of another 8 patients treated with low-dose chemotherapy Docetaxel combined with LHRH agonist.
RESULTS: The overall (groups A and B) results concerning PSA after the sixth IPT show partial effect in 8 out of 16 (50%) patients, stabilization in 4 out of 16 (25%), and progression in 4 out of 16 (25%). The median survival for all treated patients is 11,7 months (range 3-30 months). During the treatment no significant side effects were observed, and no lethal cases occurred.
CONCLUSION: In spite of the small number of the treated patients with castration-resistant prostate tumors, the preliminary results are promising and this gives us hope and expectations for future serious multicenter research over the possibilities for routine implementation of IPTLD.
Written by:
Damyanov C, Gerasimova D, Maslev I, Gavrilov V Are you the author?
Medical Center "Integrative Medicine", Deliiska Vodenitza Street, Bl. 330, 1592 Sofia, Bulgaria
Reference: ISRN Urol. 2012;2012:140182
doi: 10.5402/2012/140182
PubMed Abstract
PMID: 22649741